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Introduction 12 
13 
Human papillomavirus (HPV) is the most common sexually transmitted virus and causes a 14 
substantial burden of disease in both men and women [1]. The prevalence of HPV remains 15 
unacceptably high. In 2013-2014, approximately 45 percent of men and 40 percent of women 16 
between the ages of 18 and 59 had genital HPV infection [2].  Genital HPV infections are contracted 17 
through unprotected vaginal or anal sexual intercourse and skin-to-skin genital contact. HPV 18 
infections that result in oral or upper respiratory malignancies are mostly contracted through 19 
unprotected oral sex [3]. Most HPV infections are asymptomatic and resolve within a few months 20 
of exposure. However, the infection can progress to form pre-cancerous and cancerous lesions. HPV 21 
has been shown to be the cause of several clinically significant conditions. As of this writing, more 22 
than 100 types of papillomavirus strains that can infect humans have been identified. These have 23 
been divided into high- and low-risk types according to their risk of progressing to cancer. The high-24 
risk oncogenic variants of HPV, specifically genotypes 16 and 18, account for approximately 70% of 25 
all cases of invasive cervical cancer and cervical dysplasia worldwide [4, 5]. They also account for a 26 
smaller fraction of cancers of the vulva, vagina, anus, penis, head and neck [6]. The low-risk HPV 27 
variants of genotypes 6 and 11 are responsible for approximately 90% of benign external anogenital 28 
warts [7] and almost all cases of recurrent respiratory papillomatosis (RRP) [8, 9]. 29 
Primary prevention of HPV-related diseases is possible with vaccination. Three vaccines (Cervarix, 30 
Gardasil and Gardasil9) are currently approved for the prevention of HPV infection. All of these 31 
vaccines are active against the high-risk HPV 16 and 18 strains, while Gardasil® also protects against 32 
HPV 6 and 11. Gardasil9 was authorized in the European market in 2015 and protects against nine 33 
strains of HPV, including types 6, 11, 16, 18, 31, 33, 45, 52 and 58 [10, 11]. The availability of these 34 
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vaccines has led to the initiation of population-wide immunization programmes in most western 35 
countries. Based on previous cost-effectiveness studies, the primary aim of most HPV immunization 36 
programmes has been to protect women against cervical cancer [12-14]. However, a study 37 
published in 2012 demonstrated the relevance of the burden of HPV malignancies in men to all who 38 
pay for healthcare services (the Italian National Health System, NHS) [15]. A subsequent study 39 
demonstrated the cost-effectiveness of gender-neutral immunization in Italy [14]. Based on these 40 
findings, in 2017, the Italian Government became the first of the G9 countries to introduce a 41 
universal, recommended and free vaccination for HPV for girls and boys at the age of 12 [16]. 42 
 43 
Because of these policy changes, the aim of the study was to provide an estimate of the total, direct 44 
medical costs attributable to HPV infection, with stratification of the burden by sex as well as specific 45 
diseases using cost inputs taken from the Italian National Health Service. Furthermore, this study 46 
also calculated an aggregate measure of the total economic burden attributable to HPV 6, 11, 16, 47 
18, 31, 33, 45, 52 and 58 infections as an estimate of the potential savings due to the introduction 48 
of the nine-valent universal HPV vaccination programme. 49 
  50 
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Methods 51 
 52 
Study design: 53 
 54 
The study design was developed using the Italian National Health Service (NHS), from which the cost 55 
inputs were selected. A systematic review of the literature was conducted to identify economic and 56 
epidemiological data related to each HPV-induced disease. The review was aimed to identify the 57 
best secondary data available to produce lifetime costs per case estimates. In particular we searched 58 
for epidemiological data such as incidence and prevalence rates as well as direct cost estimates from 59 
the perspective of the Italian national payer. As a result, lifetime costs for cervical dysplasia, 60 
anogenital warts and cervical cancer were modelled based on a number of previously published 61 
studies (Table 1) [17]. Due to the lack of available information regarding RRP in the Italian context, 62 
treatment assumptions were speculated for this disease on the basis of international literature as 63 
well as tariffs applied by Italian diagnosis-related groups (DRGs).  64 
Real-world data were used to estimate hospital-based management costs of the main HPV-induced 65 
malignancies: cervical, vulvar, vaginal, penile, head and neck cancer. Specifically, hospital discharge 66 
records (HDRs) from 2010 to 2014 from the administrative archives of the Marche region were 67 
analysed to identify hospitalization rates as well as the costs associated with HPV-related diseases. 68 
This approach was followed and validated by previous publications made in this field [[18]]. Finally, 69 
outpatient costs related to these malignancies were estimated based on the latest national tariffs 70 
(2013) for specialist consultation procedures, and treatment paradigms were validated by the 71 
expert opinions of a group of clinicians. An incidence-based approach was then adopted to estimate 72 
lifetime costs per case and produce an aggregate measure of the economic burden. The relative 73 
prevalence rates of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 according to the literature were 74 
applied to estimate the aggregate fraction of costs attributable to HPV infections in Italy.  75 
Real-world data analysis:  76 
 77 
Information related to the hospital discharges (HDRs) of all accredited public and private hospitals 78 
in the Marche Region, both for ordinary and day-care regimens, were included to estimate the costs 79 
of cervical, vulvar, vaginal, penile, head and neck cancer. The total costs related to hospitalizations 80 
were calculated using the DRGs (with 2013 values) of hospitalized patients based on their age, 81 
gender and their consumption of resources during their hospital stay. The DRG system aggregates 82 
all activities, including surgical interventions, administered drugs, expended materials and 83 
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personnel for each individual diagnosis and stipulates the reimbursement tariff. This value 84 
corresponds to the total amount of all interventions provided that is to be paid to the hospital. 85 
According to the DRG-based reimbursement system, every hospitalized patient was assigned to a 86 
group of diagnostically homogeneous cases; therefore, patients with the same DRG values were 87 
assigned the same reimbursement charges.  88 
We included hospitalizations of patients who were residents of the Marche region, were older than 89 
18 years of age, and who presented one of the following codes from the International Classification 90 
of Diseases, 9th revision–Clinical Modification (ICD-9-CM) as the primary or secondary diagnosis: 91 
‘Anal cancers’ (154.2–154.8); ‘Oropharyngeal cancers’ (146.0-146.9); ‘Other female genital organs’ 92 
(184.0-184.9); and ‘Penile cancer’ (187.1-187.9). A cohort of 810 patients (40% male and 60% 93 
female) who were hospitalized in 2010 or 2011 was selected from those who did not fall into any of 94 
the reported ICD9-CM diagnosis categories and who had not had other malignant tumours in the 95 
two years prior to their first hospital admission (naïve). Subjects were included and then followed 96 
for three years after their first hospital admission. Based on expert opinions and [15], we assumed 97 
that a three-year period was appropriate in terms of resource utilization to estimate lifetime costs. 98 
In addition, outpatient visits were modelled based on the clinical pathway followed by [19] 99 
which was validated here by the clinical experts involved in the study. In particular based on 100 
the clinical guidelines and current practices, a number of procedures per each diagnose was 101 
established to represent the amount of outpatient services provided to patients lifetime. Outpatient 102 
costs were then applied based on the 2013 national tariffs for specialists’ office consultations and 103 
procedures [[15]. 104 
Literature review: 105 
 106 
Secondary data were identified through a systematic literature review. The search was carried out 107 
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 108 
guidelines [20] (Figure 1). The search was conducted in October 2017 and covered the period of 109 
1990 to 2017. The analysis was performed through the online MEDLINE (Medical Literature Analysis 110 
and Retrieval System) bibliographic archive of MEDLARS using the PubMed search system and 111 
EMBASE accessed through OVID SP. To retrieve robust data that were relevant to Italy, the inquiry 112 
was integrated with grey literature obtained from generic academic search engines (e.g., Google 113 
Scholar) and websites such as the Italian Ministry of Health, the Italian National Institute of Health 114 
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(NIH), and those of Italian scientific societies such as the Italian Society of Health Technology 115 
Assessment (SIHTA). The search keys used to conduct the literature are reported in Annex B. 116 
Screening and data extraction: 117 
 118 
Two independent researchers screened the titles and abstracts. Full-text articles were included if 119 
they met the following inclusion criteria: 1) they reported epidemiological data (incident cases by 120 
disease and the prevalence of HPV by genotype) derived from population databases, such as 121 
national surveys or registries; and 2) they reported direct cost data from the perspective of the 122 
payer and expressed monetary values for hospital DRGs and outpatient tariffs. Studies were also 123 
required to contain estimates of reported lifetime costs or appropriate data to estimate these costs. 124 
For all phases of the literature review, disagreements were resolved by discussions among the entire 125 
team to reach a consensus. 126 
Figure 1: Literature review, PRISMA 127 
Lifetime costs:  128 
 129 
An incidence-based approach was adopted in which the lifetime costs per case associated with each 130 
condition were applied to the estimated number of incident cases that were attributable to HPV.  131 
We sought to develop cost-per-case estimates that represented the current values of the total direct 132 
medical costs accrued from the time of diagnosis to the end of follow-up (Table 1).  133 
Specifically, cost estimates for cervical cancer were obtained from a published Italian study [17] that 134 
estimated the mean total direct costs for cervical cancer, including those generated by the 135 
management of disease progression and recurrence. The actual costs were not reported, although 136 
the median follow-up duration of the cohort was 23 months (range 1–89). We assumed that the 137 
mean cost per patient for primary tumour treatment (€13,122) was incurred within year 1, whereas 138 
the mean cost associated with the management of disease progression and recurrence (€9,092) was 139 
incurred in the following year, and we reduced this second-year value by 3% (€8,827). The selected 140 
discount rate (3%) reflects the opportunity costs of financing from the perspective of a public payer 141 
(the Italian NHS) according to Italian AIES (Italian Health Economics Association) guidelines [21]. 142 
Lifetime costs associated with the clinical and surgical management of cervical dysplasia were 143 
estimated from published Italian data [22, 23].  144 
The lifetime cost per patient of non-cervical malignancies was modelled on the national treatment 145 
guidelines of a previously published study [15]. Therefore, in addition to the real-world data used 146 
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to estimate the lifetime costs of hospitalization, we also included two clinical examinations 147 
conducted by specialists and two two-sector computed tomography (CT) scans per year. These costs 148 
were then reported over a 3-year follow-up period, which is consistent with the real-world data 149 
according to [15] and expert opinion. Outpatient fees were attributed to each surgical procedure 150 
and medical treatment using national outpatient tariff values (2013). Hospitalization costs (including 151 
outpatient costs) incurred after the first 12 months of treatment were discounted at a rate of 3% 152 
per year to obtain their current net value expressed in the value of the Euro in 2013.  153 
The estimated lifetime cost of anogenital warts per incident case was calculated as the sum of the 154 
mean, inflation-adjusted direct costs incurred by new patients (€416 for women and €311 for men) 155 
and the probable, discounted, inflation-adjusted mean direct costs of recurrent (€199 for women 156 
and €66 for men) and resistant (€48 for women and €92 for men) episodes observed over one year 157 
after initial diagnosis. These figures were modelled on a previously published article [24]. Probability 158 
rates were calculated based on the number of recurrent (50.6% for women and 34.8% for men) and 159 
resistant (28.2% for women and 38.5% for men) cases reported as a percentage of the annual 160 
number of newly diagnosed cases, assuming a steady state in the total number of genital warts 161 
treated in Italy [24].  162 
Finally, to estimate the lifetime cost per RRP patient, elective surgical procedures and medical 163 
treatments were selected according to published reports from the US [25, 26]. Treatment 164 
assumptions included the management of complicated respiratory infections, three acute clinical 165 
treatments, 4.4 surgical procedures, and a tracheotomy rate of 11% per year [25]. Italian DRG tariffs 166 
for 2013 were applied to the selected procedures. The duration of the disease was estimated to be 167 
4.2 years [25]. All costs incurred after the first 12 months of treatment were discounted at a rate of 168 
3% per year to obtain their current net value expressed in the value of the Euro in 2013.  169 
All costs related to each HPV-induced disease included in the study (Table 1) were adjusted for 170 
inflation in 2018 using the compound annual Italian National Consumer Price Indexes (NIC) provided 171 
by the Italian National Institute of Statistics (ISTAT).  172 
Table 1: Estimates of lifetime cost per patient by diagnosis 173 
 174 
Diagnoses 
Surgical procedures and medical 
treatments 
Direct cost 
per 
procedure or 
medical 
treatment 
Compound 
inflation 
rate ^ 
Lifetime 
direct cost 
per incident 
patient        
(2018 Euro) 
Source 
  a b a x b  
Cervical cancer      
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 Management of primary tumour €13,122 117.50% € 15,418 [17] 
 
Discounted cost of 
progression/recurrence 
after 1 year 
€8,827 
117.50% € 10,372 
[17] 
 Lifetime cost per patient €21,949 
 
€ 25,790  
Cervical dysplasia   
  
 
 Abnormal PAP smears €25 117.50% € 29 [22] 
 Colposcopies €101 117.50% € 119 [22] 
 Diagnosis of cervical dysplasia €34 117.50% € 40 [23] 
 CIN1 treatment €686 117.50% € 806 [27] 
 CIN2 treatment €1,242 117.50% € 1,459 [27] 
 CIN3 treatment €1,763 117.50% € 2,072 [27] 
 Lifetime cost per patient €4,011 
 
€ 4,525  
Anal cancer 
(Women) 
  
  
 
 Tot, lifetime hospitalizations €9,607 109.30% € 10,500 ICD9-CM (154.2-154.3;154.8) 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.7) [19] 
 Follow-up sector CT scan (x3) €74.88 102.20% € 77 Outpatient tariff (87.03) [19] 
 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €9,860 3% € 11,570  
Anal cancer (Men)   
  
 
 Tot, lifetime hospitalizations €15,876 109.30% € 17,353 ICD9-CM (154.2-154.3;154.8) 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.7) [19] 
 Follow-up sector CT scan (x3) €74.88 102.20% € 77 Outpatient tariff (87.03) [19] 
 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €16,129 3% € 18,422  
Oropharyngeal 
cancer (Women) 
  
  
 
 Tot, lifetime hospitalizations €11,210 109.30% € 12,253 ICD9-CM (146.0-146.9) [19] 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.7) [19] 
 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €11,388 3% € 13,029  
Oropharyngeal 
cancer (Men) 
  
  
 
 Tot, lifetime hospitalizations €23,096 109.30% € 25,244 ICD9-CM (146.0-146.9) 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.7) [19] 
 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €23,274 3% € 26,021  
Vulvar and 
vaginal cancer 
  
  
 
 Tot, lifetime hospitalizations €11,084 
109.30% € 12,115 ICD9-CM (184.0-184.4;184.8-
184.9) 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.26) [19] 
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 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €11,262 3% € 12,890  
Penile cancer   
  
 
 Tot, lifetime hospitalizations €7,031 109.30% € 7,685 ICD9-CM (187.1-187.9) 
 Follow-up 2 clinical examinations (x3) €20.66 102.20% € 42 Outpatient tariff (89.7) [19] 
 Follow-up sector CT scan (x3) €77.67 102.20% € 79 Outpatient tariff (87.41) [19] 
 Follow-up sector CT scan (x3) €79.47 102.20% € 81 Outpatient tariff (88.01) [19] 
 Lifetime cost per patient €7,209 3% € 8,461  
Anogenital warts 
(Women) 
  
  
 
 Direct outpatient costs for new patients €368 119.80% € 441 [24] 
 Discounted cost of recurrence after 1 
year (50.6% prob) 
€176 
119.80% € 211 
[24] 
 Discounted cost of resistance after 1 
year (28.2% prob) 
€43 
119.80% € 52 
[24] 
 Lifetime cost per patient €587 
 
€ 703  
Anogenital warts 
(Men) 
  
  
 
 Direct outpatient costs for new patients €275 119.80% € 329 [24] 
 Discounted cost of recurrence after 1 
year (34.8% prob) 
€59 
119.80% € 71 
[24] 
 Discounted cost of resistance after 1 
year (38.5% prob) 
€82 
119.80% € 98 
[24] 
 Lifetime cost per patient €416 
 
€ 498  
RRP   
  
 
 Management of complicated throat 
infection 
€5,744 
102.20% € 5,870 
DRG 79 
 Acute clinical treatment of throat 
infection (x3) 
€9,650 
102.20% € 29,587 
DRG 76 
 Minor throat surgery (x4.4) €4,378 102.20% € 19,687 DRG 63 
 Tracheostomy (11% rate) €8,737 102.20% € 982 DRG 75 
 Annual cost per patient €28,509 
 
€ 56,126  
 Lifetime cost per patient  3% € 224,860  
 ^Costs have been adjusted for 2018 inflation values using the compound annual Italian National Consumer Price Indexes 175 
[28]  from 2005 (119.8%), 2006 (117.5%), 2010 (109.3%), and 2013 (102.2%). 176 
Legend: cervical intra-epithelial neoplasia (CIN), recurrent respiratory papillomatosis (RRP), computed tomography (CT), 177 
total (Tot), prob (probability). 178 
Incidence and HPV9 genotype attribution:  179 
 180 
An estimate of the incident cases in the population over 18 years of age in Italy in 2018 [29] was 181 
obtained from the systematic literature review using the mean of the ranges provided by the 182 
selected studies (Table 3). Crude incident rates per 100,000 residents in the 2018 resident Italian 183 
population [29] were calculated (Table 2). Due to the heterogeneity of the rates reviewed and the 184 
number of diseases involved, no standardization, meta-analyses or adjustments for the pyramidal 185 
stratification of the observed population were attempted. Due to a lack of Italian epidemiological 186 
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data, the incidence of RPP was deliberately selected from the lower limit of the range cited in the 187 
literature [15]. 188 
Moreover, to estimate the costs attributable to HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, 189 
prevalence rates of HPV DNA and genotype attribution per condition were identified from the 190 
systematic review. Specifically, for each condition, we first calculated the percentage of DNA 191 
attribution to exclude all cases that were not a result of HPV infection. We then applied prevalence 192 
rates from the literature to calculate the individual fractions attributable to genotypes included in 193 
HPV9 vaccine (Table 2 and Annexe A). These values were used to calculate the fraction of the total 194 
economic burden of HPV-induced malignancies attributable to the nine genotypes by both disease 195 
and sex according to the number of estimated incident cases. 196 
Table 2: Incidence rates, the prevalence of HPV, and HPV9 genotype fractions  197 
 198 
Diagnoses Incidence rates (per 100,000) HPV DNA+ (%) HPV9 fraction Source 
Cervical cancer 4.5 100.0% 89,4% [30-32] 
Abnormal PAP smears 699.2 100.0% 91,5% [15] 
Colposcopies 195.4 100.0% 94,0% [15] 
Diagnosis of cervical dysplasia 657.1 100.0% 35,0% [15] 
CIN1 treatment 35.9 100.0% 75,0% [15, 32, 33] 
CIN2 treatment 9.1 100.0% 72,5% [15, 32, 33] 
CIN3 treatment 10.0 100.0% 57,2% [15] 
Anal cancer 1.7 88.0% 89.8% [30, 34] 
Oropharyngeal cancer 15.5 40.0% 73.7% [35, 36] 
Vulvar and vaginal cancer 2.3 36.6% 86.4% [31] 
Penile cancer 0.8 50.0% 81.6% [30, 37] 
Anogenital warts 241.6 100.0% 90.0% [15, 34] 
RRP 0.4 100.0% 95.0% [38-40] 
Legend: cervical intra-epithelial neoplasia (CIN), recurrent respiratory papillomatosis (RRP). 199 
Statistical analyses: 200 
 201 
Probabilistic and Deterministic Sensitivity Analyses (PSA and DSA) were developed to account for 202 
the variability of data used in the model. The PSA employed the differences found in the examined 203 
sources indicating minimum and maximum values of the uncertainty distribution for each 204 
parameter. The probabilistic distribution was prepared by applying normally reported values for the 205 
development of probabilistic models in economic evaluations, distinguishing between costs (gamma 206 
distribution) and epidemiological parameters (beta distribution) [41]. The distribution of each 207 
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parameter was then used to perform 5,000 Monte Carlo simulations to obtain interval estimates 208 
(95% Confidence Interval (CI)) for the main epidemiological and economic data (Annex C). 209 
The DSA was performed by adjusting each parameter to the highest and lowest possible values of 210 
the data obtained from the systematic review with a one-way approach. When a plausible range 211 
was not available from the literature, we assumed a variation of 10%. 212 
The critical parameters used to assess the uncertainty were: the number of incident cases per year, 213 
the HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58, genotype attributions and cost parameters.  We 214 
measured the impact of inserting the highest and lowest values for: (a) all diseases, (b) only 215 
oncologic diseases (defined as the sum of cervical, anal, oropharyngeal, vulvar, vaginal and penile 216 
cancers) (c) non-oncologic (cervical dysplasia, anogenital warts and RRP). 217 
Cost estimates of innovative therapeutic options not included in the DRG tariffs:  218 
 219 
The DRG tariffs used as the main inputs for evaluating the direct costs of hospitalization did not 220 
include the costs of innovative therapeutic options that were added to the treatment guidelines for 221 
HPV-induced malignancies after 2013. The costs of these new drugs were actually debited to a 222 
National Account (named “File F”), which was specifically created to account for highly innovative 223 
therapeutic options. However, the administrative costs were paid for by the DRG tariff. File F is not 224 
accessible and does not provide information on the use of innovative drugs by indication. Therefore, 225 
identifying the resources allocated from File F used to treat HPV-induced malignancies is impossible. 226 
Ignoring these costs, however, would significantly underestimate the burden of HPV-induced 227 
diseases carried by the NHS. Therefore, we used the scenario analysis [42] method to estimate a 228 
range of credible costs for the innovative therapies used to treat HPV-induced malignancies. 229 
Following the latest guidelines of the Associazione Italiana di Oncologia Medica (AIOM) for the 230 
treatment of HPV-induced malignancies, two innovative therapeutic options were identified: 231 
- Cetuximab (Erbitux), indicated for the treatment of head and neck cancer; 232 
- Bevacizumab (Avastin), indicated for the treatment of recurrent or refractory cervical 233 
cancer. 234 
The treatment and cost inputs used to determine the three scenarios are reported in Annex A. 235 
 236 
Results 237 
 238 
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The annual incidence of the nine HPV-related conditions corresponded to approximately 1.1 million 239 
cases of which 975 thousand associated to cervical conditions (86%), and 158 thousand to non-240 
cervical (14%). In 2018, the total direct costs (expressed relative to the 2018 Euro) associated with 241 
the annual incident cases of cervical cancer, cervical dysplasia, vulvar, vaginal, anus, penis and head 242 
and neck cancers, anogenital warts, and RRP in Italy were estimated to be €542.7 million, with a 243 
credible range of €346.7 - €782.0 million. These costs could increase considering also the impact of 244 
innovative therapies for cancers treatment included in the scenario analysis with a plausible range 245 
between €16.2 and €37.5 million. The fraction attributable to the nine HPV9 genotypes included in 246 
our base case analysis, without considering the impact of innovative therapies, was €329.5 million 247 
(range €157.0 - €564.9 million), accounting for approximately 61% of the total annual burden of 248 
HPV-related diseases in Italy. 249 
Cervical conditions: 250 
 251 
The total cost estimate for cervical conditions was €149.9 million (range €132.0 - €168.9 million), 252 
which corresponds to 28% of the total economic burden associated with HPV-related diseases in 253 
Italy, (Table 5). Of this amount, €69.7 (range €59.1 - €81.2 million) and €80.2 million (range €66.2 - 254 
€95.6 million) were due to cervical cancer and total cervical dysplasia, respectively – estimates that 255 
include diagnosis, colposcopies, PAP smears and cervical neoplasia (CIN1/2/3). Additionally, the 256 
total annual cost associated with the management of cervical lesions, including the diagnosis and 257 
treatment of CIN1/2/3 stages, was €54.0 million (range €41.0 - €68.7 million). 258 
The fraction of cervical conditions attributable to HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was 259 
estimated to be €118.3 million (range €104.2 - €133.3 million), 53% of which was related to cervical 260 
cancers (€62.3 million, range €52.6 - €72.8).  261 
Non-cervical malignancies:  262 
 263 
We evaluated the direct costs related to the treatment and follow-up of HPV-related cases of seven 264 
non-cervical malignancies: cancer of the anus, oropharynx, vulva, vagina, and penis, anogenital 265 
warts and RPP. The economic burden associated with non-cervical conditions was €392.9 million, 266 
with a range of €206.3 to €638.4 million. The amount corresponds to 72% of the total costs 267 
associated with HPV-related diseases in Italy. Oropharyngeal cancers were responsible for the 268 
highest annual burden of direct costs (€215.7 million, €187.0 for men and €28.7 for women), 269 
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followed by anogenital warts (€85.9 million, €41.2 for men and €44.6 for women) and RPP (€53.6 270 
million). The costs related to all HPV-related diseases included in our study are reported in Table 5.  271 
According to our systematic review, HPV virus were responsible for 36.6% of vulvar and vaginal 272 
cancers and 40% of oropharyngeal cancers, respectively, as well as 88% and 50% [30] of anal and 273 
penile cancers, respectively. The estimated fractions of the total annual direct costs attributable to 274 
HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58-induced non-cervical malignancies were €211.2 million 275 
(range €58.5 - €460.1 million), 61% of which was attributable to HPV 6 and 11.  276 
 277 
Cost of innovative therapies not included in DRG tariffs. 278 
 279 
Table 4 reports the outcomes of the scenario analysis. Three scenarios were obtained by varying the 280 
potential number of patients treated and the future availability of similar treatments at a reduced 281 
price. The credible range of the incremental costs allocated to innovative treatments of HPV-282 
induced malignancies was €16.2 - €37.5 million. This range represents a significant incremental cost 283 
compared to the DRG tariffs for the HPV-induced malignancies, ranging from 12.8% to 29.8%.  284 
The availability of similar therapies would reduce the incremental cost by approximately 22%.285 
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Table 3: Total lifetime costs and HPV-9 attributable fraction  
 
Diagnoses 
Estimated number of incident cases 
per year 
Total lifetime direct costs per disease        
  (mill Euro) 
HPV9  attributable costs  
 (mill Euro) 
a Cervical cancer 
(CI 95%) 
2,698 € 69.7 € 62.3 
 (2,502-2,902)  (€59.1-€81.2)  (€52.6-€72.8) 
b Abnormal PAP smears 422,922 € 12.3 € 11.2 
 (CI 95%) (345,068-507,585) (€9.1-€15.8) (€7.8-€15.1) 
c Colposcopies 118,214 € 14.0 € 13.1 
 (CI 95%) (95,649-142,480) (€10.3-€18.2) (€9.1-€17.8) 
d Diagnosis of cervical dysplasia 397,444 € 15.9 € 5.6 
 (CI 95%) (321,588-480,112) (€11.7-€20.6) (€3.8-€7.6) 
e CIN1 treatment 21,715 € 17.5 € 13.1 
 (CI 95%) (17,706-26,141) (€13-€22.6) (€9.3-€17.6) 
f CIN2 treatment 5,532 € 8.0 € 5.8 
 (CI 95%) (1,998-10,735) (€2.8-€16) (€1.9-€11.8) 
g CIN3 treatment 6,047 € 12.6 € 7.2 
 (CI 95%) (2,290-11,646) (€4.5-€24.6) (€2.5-€14.4) 
h Total cervical lesions (d + e + f + g) 430,738 € 54.0 € 31.7 
 (CI 95%) (35,4125-513,625) (€41-€68.7) (€23.3-€41.3) 
i Total cervical dysplasia (b + c + h) 971,874 € 80.2 € 56.0 
 (CI 95%) (857,453-1,090,683) (€66.2-€95.6) (€46-€67.1) 
l Total cervical conditions (a + i) 974,572 € 149.9 € 118.3 
 (CI 95%) (860,140-1,093,375) (€132-€168.9) (€104.2-€133.3) 
m Anal cancer (women) 620 € 7.2 € 5.7 
 (CI 95%) (528-720) (€5.6-€8.9) (€4.3-€7.3) 
n Anal cancer (men) 437 € 8.0 € 6.4 
 (CI 95%) (360-522) (€6.1-€10.3) (€4.6-€8.4) 
o Oropharyngeal cancer (women) 2,200 € 28.7 € 8.4 
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 (CI 95%) (2,168-2,232) (€23.6-€34.3) (€6.4-€10.8) 
p Oropharyngeal cancer (men) 7,200 € 187.0 € 55.1 
 (CI 95%) (7,184-7,216) (€153.3-€224.1) (€41.2-€70.9) 
q Vulvar and vaginal cancer 1,418 € 18.3 € 5.8 
 (CI 95%) (1,275-1,566) (€14.6-€22.3) (€4.4-€7.3) 
r Penile cancer 494 € 4.2 € 1.7 
 (CI 95%) (411-582) (€3.2-€5.3) (€1.3-€2.2) 
s Anogenital warts (women) 63,447 € 44.6 € 40.1 
 (CI 95%) (51,697-76,430) (€34.5-€56) (€28.5-€53.6) 
t Anogenital warts (men) 82,674 € 41.2 € 37.1 
 (CI 95%) (67,432-99,496) (€32.1-€51.5) (€26.4-€49.5) 
u RRP 249 € 53.6 € 51.0 
 (CI 95%) (0-1,660) (€0-€372.8) (€0-€356) 
v Total non-cervical conditions (m + n + o + p + q + r + s + t 
+ u) 
158,739 € 392.9 € 211.2 
 (CI 95%) (139,079-179,749) (€206.3-€638.4) (€58.5-€460.1) 
z Total burden (l + v) 1,133,312 € 542.7 € 329.5 
 (CI 95%) (1,016,911-1,253,343) (€346.7-€782) (€157-€564.9) 
 
Legend: cervical intra-epithelial neoplasia (CIN), recurrent respiratory papillomatosis (RRP). 
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Table 4: Credible range of incremental direct costs of the innovative therapies not included in 1 
DRG tariffs 2 
 
Base case:   
(HPV9 
burden) 
Scenario 1:            
CRT H&N + 
bevacizumab 
recurrent CC 
Scenario 2:        
CRT + CCT in 
H&N + 
bevacizumab 
for recurrent 
& metastatic 
CC 
Scenario 3:             
=Scenario 2 
but 
biosimilars 
available 
(25% off) 
Source 
Base case - Oropharyngeal cancer 
    
 
Incident patients infected by HPV9-susceptible 
strains 
2,771 2,771 2,771 2,771 
 
Cost/patient € 22,980 € 22,980 € 22,980 € 22,980  
Total cost (Euro mill) € 63.7 € 63.7 € 63.7 € 63.7  
Incremental Cetuximab scenarios 
    
 
Cetuximab + RT in patients >70 years (28% of total 
eligible) 
 
776 776 776 
 
Incremental cost of Cetuximab added to RT/patient 
 
€ 8,133 € 8,133 € 6,133 [43] 
Total incremental cost (Euro mill) 
 
€ 6.3 € 6.3 € 4.8 
 
Cetuximab + CT in Stage III-IV patients in good 
performance condition (80%) 
  
€ 443.4 € 443.4 
 
Incremental cost of Cetuximab added to CT/patient 
  
€ 5,201.0 € 3,907.3 
[43] 
Total incremental cost (Euro mill) 
  
€ 2.3 € 1.7 
 
Base Case - Cervical Cancer 
    
 
Incident patients infected by HPV9-susceptible 
strains 
 2,412   2,412   2,412   2,412  
 
Treatment cost/patient  € 25,790   € 25,790   € 25,790   € 25,790   
Total cost (Euro mill)  € 62   € 62   € 62   € 62   
Incremental Bevacizumab scenarios 
    
 
Incident cervical patients HPV9+ and VEGF+ (60% 
of incident) 
 
€ 1,447 € 1,447 € 1,447 
[44] 
Recurrent patients (31% of incident VEGF+) 
 
€ 449 € 449 € 449 
[45] 
Incremental cost of Bevacizumab added to CT 
 
€ 21,966 € 21,966 € 16,475 
 
Total incremental cost (Euro mill) 
 
€ 10 € 10 € 7 
 
Metastatic patients (60% of incident VEGF+) 
  
€ 868 € 868 
[45] 
Incremental cost of Bevacizumab added to CT 
  
€ 21,966 € 16,475 
[46] 
Total incremental cost (Euro mill) 
  
€ 19.07 € 14.31 
 
TOTAL TREATMENT COST PER SCENARIO (Euro 
mill) 
    
 
INCREMENTAL COST vs BASE CASE (Euro mill) 
€ 125.9 € 142.1 € 163.4 € 154.1 
 
Incremental cost as a % of Base case 
 
€ 16.2 € 37.5 € 28.2 
 
Legend: oropharyngeal cancer (OPC), cetuximab (C), radiation therapy (RT), chemotherapy (CT), vascular endothelial 3 
growth factor (VEGF), cervical cancer (CC).   4 
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The fraction of HPV9-genotype costs attributable to men was equal to €137.7, while women 5 
accounted for €194.4. This corresponded to 58% of total costs attributable to HPV9 infections for 6 
women, whereas men accounted for 42%. On the other hand, the economic burden of HPV 6, 11, 7 
16, 18, 31, 33, 45, 52 and 58 infections that were related to non-cervical conditions was higher for 8 
men than women (64.4% vs 35.6% of the total, respectively), (Figure 2).  9 
 10 
Figure 2: Fractions of HPV 9 costs by gender  11 
 12 
 13 
Legend: recurrent respiratory papillomatosis (RRP). 14 
 15 
 16 
The Tornado chart shown in Figure 3 shows that the uncertainty in our evaluation of the economic 17 
burden of HPV9-related diseases is mostly associated with the range of possible incidence rates for 18 
all groups of disease and costs. 19 
Figure 3: Deterministic Sensitivity Analysis (DSA) 20 
Legend: Oncologic: cervical, anal, oropharyngeal, vulvar, vaginal and penile cancers  21 
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Discussion 22 
 23 
 24 
The purpose of this analysis was to estimate the economic burden of HPV-related diseases in Italy. 25 
Our study attempted to measure the direct costs from the real world data perspective of the Italian 26 
National Health Service. The authors adopted a real-world data approach to estimate lifetime costs 27 
and conducted a systematic literature review to construct our estimation models with the most 28 
recent data available. Additionally, we included the nine HPV genotypes included in the new nine-29 
valent vaccine that was made available in Europe in the last two years. Therefore, the present study 30 
is a first attempt to measure the economic burden of HPV-related diseases in Italy considering the 31 
newly available vaccine and data. By estimating the resource consumption attributable to the nine 32 
genotypes, we aim to predict the effects of both the 2017-2019 National Immunization Plan and the 33 
strategies recently adopted in Italy and to inform future public health decisions.  34 
According to the results of this study, costs related to CIN1 treatment, vaginal cancer and cervical 35 
cancer were the most heavily influenced when including five HPV genotypes that accounted for 28% 36 
of their total cost on average. Furthermore, the economic burden among men represented more 37 
than one-third (42%) of the total direct costs of HPV9 genotype-related diseases, including cervical 38 
conditions, which is consistent with previously published data [6, 15] and with the effort to extend 39 
the anti-HPV immunization programme to include boys in the National Immunization Plan 2017-19. 40 
The present study has several limitations. First, real-world data from administrative archives were 41 
only available for anal, head and neck, vulvar, vaginal and penile cancers, and published Italian 42 
sources of cost data were limited. Additionally, the quality of the available information was variable. 43 
Therefore, the use of different data sources may have diminished the comprehensiveness of our 44 
data. Specifically, the use of administrative data required certain assumptions to consistently 45 
estimate the lifetime costs from different data sources. Hospital discharge forms may have 46 
codification problems; therefore some information may be missing and/or be wrongly reported. In 47 
this case, our analysis may have missed this information (due to the inclusion criteria), with the risk 48 
of underestimating the economic and epidemiological burden of the considered HPV-related 49 
diseases. Additionally, not all diseases led to hospitalization and this may be a further source of 50 
underestimation. Additionally, due to the scarcity of available data, we did not include drug 51 
utilization in our estimates. These limitations should be considered in future research; however, in 52 
our opinion, they do not undermine the validity of the cost estimates in the present study or their 53 
estimated impact on the total economic burden of HPV-related diseases. Future research should 54 
18 
 
address these gaps in epidemiological and cost data to reduce the uncertainty associated with the 55 
present estimates. In conclusion, the present analysis is the first to provide a snapshot of the current 56 
state of resource utilization in Italy and the expected economic effects resulting from the 2017-2019 57 
National Immunization Plan. Therefore, we believe that this analysis may provide a tool for keeping 58 
records of the expected economic effects over time.  59 
 60 
  61 
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